Ardmore Shipping-Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy

Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy

Ardmore Shipping(US:ASC) Prnewswire·2025-09-22 00:10

-Â Â Â Â Â Â Â Â The g astrointestinal ( GI ) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). Â The incidence of vomiting was 6.7% in ASC47 in combination with semaglutide groupÂ compared to Â 57.1% in the semaglutide monotherapy group. ...